Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-23
2006-05-23
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S262200, C548S267600, C546S169000, C514S383000
Reexamination Certificate
active
07049324
ABSTRACT:
a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1and L2are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(═O), or a direct bond; R1is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; ═Z1—Z2═Z3— represents a radical of formula ═N—N═CH— (a-1), ═N—CH═N— (a-2), ═CH—N═N— (a-3); X is SO2, (CH2)nwherein n is 1 to 4, C(═O), C(═S), or a direct bond, R2is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio; R3is aryl, —NR5R6, a substituted or unsubstituted C1-14heterocycle, or C2-4alkenediyl substituted with a substituted or unsubstituted C1-14heterocycle or aryl; R4is hydrogen, aryl, C3-7cycloalkyl, C1-6alkyl or C1-6alkyl substituted with C3-7cycloalkyl, hydroxycarbonyl, C1-4alkyloxycarbonyl or aryl; R5and R6are each independently selected from hydrogen, a substituted or unsubstituted C1-14heterocycle, aryl, C1-12alkyl and C1-12alkyl substituted with one or more substituents selected from hydroxy, aryl, aryloxy or a substituted or unsubstituted C1-14heterocycle.
REFERENCES:
patent: 4243408 (1981-01-01), Chan
patent: 5217985 (1993-06-01), Reitz
patent: 5710171 (1998-01-01), Dinsmore
patent: 5780488 (1998-07-01), Bergman
patent: 5817678 (1998-10-01), Kim
patent: 5854264 (1998-12-01), Anthony
patent: 5854265 (1998-12-01), Anthony
patent: 5869579 (1999-02-01), Hodges et al.
patent: 5872136 (1999-02-01), Anthony
patent: 5874452 (1999-02-01), Anthony
patent: 5880140 (1999-03-01), Anthony
patent: 5883105 (1999-03-01), Anthony
patent: 5891889 (1999-04-01), Anthony
patent: 5932590 (1999-08-01), Ciccarone
patent: 5939439 (1999-08-01), Anthony
patent: 5939557 (1999-08-01), Anthony
patent: WO 9324465 (1993-12-01), None
patent: WO 9727853 (1997-08-01), None
patent: WO 9736585 (1997-10-01), None
patent: WO 9738881 (1997-10-01), None
patent: WO 9738897 (1997-10-01), None
patent: WO 9828980 (1998-07-01), None
patent: WO 0136395 (2001-05-01), None
Breslin Henry Joseph
De Corte Bart Lieven Daniel
End David William
Liu Li
Saha Ashis Kumar
Lopez Gabriel
Shameem Golam M M
LandOfFree
Triazoles as farnesyl transferase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazoles as farnesyl transferase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazoles as farnesyl transferase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3548803